In the present study, we investigated the effects of a novel and highly selective ERβ-selective agonist, OSU-ERb-12 (16), to inhibit preclinical models of ERα+ breast cancer and to counter endocrine and CDK4/6i resistance in vitro. Here, ESR1 is linked to breast cancer.